Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EVX 01

Next Previous
Drug Profile

EVX 01

Alternative Names: EVAX-01-CAF09b; EVX-01; EVX-01 NeoPepVac; NPV-ds001-CAF09b

Latest Information Update: 09 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Evaxion Biotech
  • Developer Evaxion Biotech; Merck & Co
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant melanoma
  • Phase I/II Bladder cancer; Non-small cell lung cancer

Most Recent Events

  • 28 Apr 2025 Updated efficacy data from a phase IIb trial in Malignant melanoma released by Evaxion Biotech
  • 15 Jan 2025 Evaxion Biotech completes enrolment and dosing in phase-II clinical trial in Malignant melanoma (Combination therapy, Metastatic disease, Late-stage disease, Inoperable/Unresectable) in Australia (IM) (NCT05309421) (EudraCT2022-000899-19)
  • 23 Sep 2024 Immunogenicity data from phase-IIb trial in Malignant melanoma released by Evaxion Biotech

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top